Kimiko Domoto‐Reilly
A5028293125- Dementia and Cognitive Impairment Research
- Amyotrophic Lateral Sclerosis Research
- Alzheimer's disease research and treatments
- Neurobiology of Language and Bilingualism
- Parkinson's Disease Mechanisms and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Health, Environment, Cognitive Aging
- Neurological diseases and metabolism
- Prion Diseases and Protein Misfolding
- Folate and B Vitamins Research
- Functional Brain Connectivity Studies
- Advanced Neuroimaging Techniques and Applications
- Language Development and Disorders
- Cerebrovascular and genetic disorders
- Medical Imaging Techniques and Applications
- Cholinesterase and Neurodegenerative Diseases
- Epilepsy research and treatment
- Assistive Technology in Communication and Mobility
- Genomics and Rare Diseases
- Cognitive Functions and Memory
- Neurological and metabolic disorders
- Advanced MRI Techniques and Applications
- Reading and Literacy Development
- Mental Health and Psychiatry
- Technology Use by Older Adults
University of Washington
2016-2025
Seattle Pacific University
2022-2025
VIB-UAntwerp Center for Molecular Neurology
2024
University of Antwerp
2024
University of California, Los Angeles
2013-2024
Pacific Northwest University of Health Sciences
2024
Brotman Baty Institute
2024
Swedish Medical Center
2024
Massachusetts General Hospital
2011-2022
Harvard University
2002-2022
Objective Recent studies have shown that positron emission tomography (PET) tracer AV-1451 exhibits high binding affinity for paired helical filament (PHF)-tau pathology in Alzheimer's brains. However, the ability of this ligand to bind tau lesions other tauopathies remains controversial. Our goal was examine correlation vivo and postmortem patterns three autopsy-confirmed non-Alzheimer tauopathy cases. Methods We quantified retention [F-18]-AV-1451 performed autoradiography, [H-3]-AV-1451...
Abstract Introduction We created global rating scoring rules for the CDR ® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) conduct clinical trials in FTLD. Methods The was applied 970 sporadic familial participants from baseline visit of Advancing Research Treatment Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation Familial Dementia Subjects (LEFFTDS). Each eight domains equally weighed determining score. An interrater reliability study...
Alzheimer's disease neuropathologic change (ADNC) is defined by progressive accumulation of β-amyloid plaques and hyperphosphorylated tau (pTau) neurofibrillary tangles across diverse regions brain. Non-demented individuals who reach advanced age without significant ADNC are considered to be resistant AD, while those burdened with resilient. Understanding mechanisms underlying resistance resilience may provide important clues treating and/or preventing AD associated dementia. criteria for...
We tested the hypothesis that plasma neurofilament light chain (NfL) identifies asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)-causing mutations at risk disease progression.Baseline NfL concentrations were measured with single-molecule array in original (n = 277) and validation 297) cohorts. C9orf72, GRN, MAPT mutation noncarriers from same families classified by severity (asymptomatic, prodromal, full phenotype) using CDR Dementia Staging Instrument plus behavior...
At present, no research criteria exist for the diagnosis of prodromal behavioural variant frontotemporal dementia (bvFTD), though early detection is high importance. Thus, we sought to develop and validate a proposed set bvFTD, termed 'mild and/or cognitive impairment in bvFTD' (MBCI-FTD). Participants included 72 participants deemed have bvFTD; this comprised 55 carriers pathogenic mutation known cause lobar degeneration, 17 individuals with autopsy-confirmed degeneration. All had mild...
Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of susceptibility, diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows promise as biomarker, but studies have largely focused only on core FTD syndromes, often grouping patients with different diagnoses. To expedite the clinical translation NfL, we avail ARTFL LEFFTDS Longitudinal Lobar Degeneration (ALLFTD) study resources conduct comprehensive investigation plasma NfL across syndromes in...
Importance Frontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers trial recruitment success, but no such tools validated for FTLD. Objective To evaluate the reliability validity of measures remote FTLD evaluations. Design, Setting, Participants In this cohort study conducted from...
Accurate epidemiologic estimates for dementia are lacking American Indians, despite substantive social and health disparities.
Background: Primary progressive aphasia (PPA) is a devastating neurodegenerative syndrome involving the gradual development of aphasia, slowly impairing patient’s ability to communicate. Pharmaceutical treatments do not currently exist and intervention often focuses on speech language behavioural therapies, although further investigation warranted determine how best harness functional benefits. Efforts develop pharmaceutical have been hindered by lack standardised methods monitor disease...
The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Longitudinal Evaluation of Familial Dementia Subjects (LEFFTDS) consortia are two closely connected studies, involving multiple North American centers that evaluate both sporadic familial frontotemporal dementia (FTD) participants study longitudinal changes.
Abstract Introduction Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction clinically relevant hallmark and may be marker progression. Methods Ninety‐three mutation carriers with no symptoms or minimal/questionable ( MAPT , n = 31; GRN 28; C9orf72 34; Clinical Dementia Rating scale plus NACC Module < 1) 78 noncarriers...
Abstract Introduction Some models of therapy for neurodegenerative diseases envision starting treatment before symptoms develop. Demonstrating that such treatments are effective requires accurate knowledge when would have started without treatment. Familial frontotemporal lobar degeneration offers a unique opportunity to develop predictors symptom onset. Methods We created dementia risk scores in 268 familial family members by entering covariate‐adjusted standardized estimates brain atrophy...
Leisure activities impact brain aging and may be prevention targets. We characterized how physical cognitive relate to health for the first time in autosomal dominant frontotemporal lobar degeneration (FTLD).
Abstract Objective Autosomal‐dominant familial Alzheimer disease ( AD ) is caused by variants in presenilin 1 PSEN ), 2 and amyloid precursor protein APP ). Previously, we reported a rare frameshift variant an early‐onset case p.K115Efs*11). In this study, characterize second family with the same analyze cellular transcripts from both patient fibroblasts brain lysates. Methods We combined genomic, neuropathological, clinical, molecular techniques to K115Efs*11 two families. Results...
Abstract Introduction Behavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding the generalizability assessments and treatments. Methods A total 135 sporadic (s‐bvFTD; mean age 63.3 years; 34% female) 99 familial (f‐bvFTD; 59.9; 48% bvFTD participants were identified. f‐bvFTD cases included 43 with known presumed chromosome 9 open reading frame 72 ( C9orf72 ) gene expansions,...
Background Measuring systemic inflammatory markers may improve clinical prognosis and help identify targetable pathways for treatment in patients with autosomal dominant forms of frontotemporal lobar degeneration (FTLD). Methods We measured plasma concentrations IL-6, TNFα YKL-40 pathogenic variant carriers ( MAPT, C9orf72, GRN ) non-carrier family members enrolled the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration consortium. evaluated associations between baseline...
This pilot study evaluated a web-based intervention, guided by problem-solving therapy, to address challenges faced caregivers of individuals with Lewy body dementia (LBD). A quasi-experimental single-arm was conducted 39 family (mean age: 67.62 years; 69% women; 95% White). The 8-week program, Virtual Online Communities for Aging Life Experiences Body Dementia (VOCALE LBD), included discussion platform, peer support, training, and practice. Measurements were taken at baseline,...
Abstract Background Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and underlying causative pathology. Blood glial fibrillary acidic protein (GFAP) has garnered attention as a FTD biomarker. However, investigations GFAP in have been hampered symptomatic histopathologic heterogeneity small cohort sizes contributing to inconsistent findings. Therefore, we evaluated plasma biomarker compared its...
Aim Cognitive and behavioral phenomena define variant frontotemporal dementia (bvFTD), but neuropsychiatric symptoms (NPS) outside the core criteria are common throughout illness. Identifying how NPS cluster in bvFTD may guide development of future therapies. Methods Participants ( n = 354) with sporadic genetic were enrolled ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Consortium. Dementia stage was defined as early (CDR® plus NACC FTLD ≤1) or advanced ≥1). Baseline annual...